NASDAQ · Biotechnology · USD
Cadrenal Therapeutics, Inc. (CVKD) Stock Analysis
Cadrenal Therapeutics, Inc. (CVKD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
CVKD Key Statistics
As of Oct 21, 2026Trading
- Open
- $1.02
- Previous Close
- $1.04
- Day's Range
- 1.00–1.03
- 52-Week Range
- 0.82–14.21
- Volume
- 28.18K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.95
Valuation
- Market Cap
- $3.64M
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −4.91
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$13.24M
- Shares Outstanding
- 3.57M
- 1-Year Return
- −92.28%
Dividend and dates
- Avg Volume
- 468.75K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, CVKD closed at $1.02, −92.28% over 1 year.
Cadrenal Therapeutics, Inc. (CVKD) has a market capitalization of $3.64M.
In fiscal 2025, CVKD reported revenue of $0.00.
CVKD Stock Return by Calendar Year
Cadrenal Therapeutics, Inc. (CVKD) return since Jan 2023: what $10,000 became
- 1 year
- $10,000 $772
- −92.28%
- 3 years
- $10,000 $1,293
- −87.07%
- Since Jan 2023
- $10,000 $165
- −98.35%
If you had invested $10,000 in Cadrenal Therapeutics, Inc. (CVKD) at the close on January 20, 2023, the earliest close on record here, it would have been worth $165 at the close on October 21, 2026: −98.35% in total, −66.52% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −84.96% |
| 2025 | −53.21% |
| 2024 | +30.54% |
| 2023 | −82.04% |
As of October 21, 2026.
CVKD Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$13.24M | — |
| 2024 | $0.00 | −$10.65M | — |
| 2023 | $0.00 | −$8.36M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$13.46M | −$13.24M | — |
| 2024 | $0.00 | — | −$10.96M | −$10.65M | — |
| 2023 | $0.00 | — | −$7.63M | −$8.36M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
YahooCadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
YahooCadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
YahooCadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
YahooCVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
YahooCadrenal Therapeutics Announces FDA's Feedback At Type D Meeting For CAD-1005 Inhibitor To Treat Heparin-Induced Thrombocytopenia
Benzinga
All 7 articles ↓Show fewer ↑
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B